346 related articles for article (PubMed ID: 25936330)
1. Effects of Lipoprotein apheresis on the Lipoprotein(a) levels in the long run.
Groß E; Hohenstein B; Julius U
Atheroscler Suppl; 2015 May; 18():226-32. PubMed ID: 25936330
[TBL] [Abstract][Full Text] [Related]
2. Actual situation of lipoprotein apheresis in Saxony in 2013.
Emmrich U; Hohenstein B; Julius U
Atheroscler Suppl; 2015 May; 18():215-25. PubMed ID: 25936329
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients with LDL- or Lp(a) hyperlipoproteinemia: Findings gathered from more than 36,000 treatments at one center in Germany.
Heigl F; Hettich R; Lotz N; Reeg H; Pflederer T; Osterkorn D; Osterkorn K; Klingel R
Atheroscler Suppl; 2015 May; 18():154-62. PubMed ID: 25936320
[TBL] [Abstract][Full Text] [Related]
4. Actual situation of lipoprotein apheresis in patients with elevated lipoprotein(a) levels.
Julius U; Tselmin S; Schatz U; Fischer S; Birkenfeld AL; Bornstein SR
Atheroscler Suppl; 2019 Dec; 40():1-7. PubMed ID: 31818437
[TBL] [Abstract][Full Text] [Related]
5. Detailed description of the cardiovascular situation in patients who have started lipoprotein apheresis treatment.
Schampera S; Fischer S; Weiss N; Julius U
Atheroscler Suppl; 2015 May; 18():209-14. PubMed ID: 25936328
[TBL] [Abstract][Full Text] [Related]
6. Lipoprotein apheresis for Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease--Additional particular aspects of the Pro(a)LiFe multicenter trial.
Klingel R; Heibges A; Fassbender C
Atheroscler Suppl; 2015 May; 18():35-40. PubMed ID: 25936302
[TBL] [Abstract][Full Text] [Related]
7. Most significant reduction of cardiovascular events in patients undergoing lipoproteinapheresis due to raised Lp(a) levels - A multicenter observational study.
Schatz U; Tselmin S; Müller G; Julius U; Hohenstein B; Fischer S; Bornstein SR
Atheroscler Suppl; 2017 Nov; 30():246-252. PubMed ID: 29096845
[TBL] [Abstract][Full Text] [Related]
8. Clinical benefit of long-term lipoprotein apheresis in patients with severe hypercholesterolemia or Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease.
Heigl F; Hettich R; Lotz N; Reeg H; Pflederer T; Osterkorn D; Osterkorn K; Klingel R
Clin Res Cardiol Suppl; 2015 Apr; 10(Suppl 1):8-13. PubMed ID: 25672934
[TBL] [Abstract][Full Text] [Related]
9. Lipoprotein apheresis in patients with peripheral artery disease and hyperlipoproteinemia(a).
Poller WC; Dreger H; Morgera S; Berger A; Flessenkämper I; Enke-Melzer K
Atheroscler Suppl; 2015 May; 18():187-93. PubMed ID: 25936325
[TBL] [Abstract][Full Text] [Related]
10. Effects of lipoprotein apheresis on PCSK9 levels.
Julius U; Milton M; Stoellner D; Rader D; Gordon B; Polk D; Waldmann E; Parhofer KG; Moriarty PM
Atheroscler Suppl; 2015 May; 18():180-6. PubMed ID: 25936324
[TBL] [Abstract][Full Text] [Related]
11. Prevention of cardiovascular complications in patients with Lp(a)-hyperlipoproteinemia and progressive cardiovascular disease by long-term lipoprotein apheresis according to German national guidelines.
Klingel R; Heibges A; Fassbender C;
Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):38-43. PubMed ID: 28185214
[TBL] [Abstract][Full Text] [Related]
12. Specific Lipoprotein(a) apheresis attenuates progression of carotid intima-media thickness in coronary heart disease patients with high lipoprotein(a) levels.
Ezhov MV; Safarova MS; Afanasieva OI; Pogorelova OA; Tripoten MI; Adamova IY; Konovalov GA; Balakhonova TV; Pokrovsky SN
Atheroscler Suppl; 2015 May; 18():163-9. PubMed ID: 25936321
[TBL] [Abstract][Full Text] [Related]
13. Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization.
Roeseler E; Julius U; Heigl F; Spitthoever R; Heutling D; Breitenberger P; Leebmann J; Lehmacher W; Kamstrup PR; Nordestgaard BG; Maerz W; Noureen A; Schmidt K; Kronenberg F; Heibges A; Klingel R;
Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):2019-27. PubMed ID: 27417585
[TBL] [Abstract][Full Text] [Related]
14. The German Lipoprotein Apheresis Registry (GLAR) - almost 5 years on.
Schettler VJJ; Neumann CL; Peter C; Zimmermann T; Julius U; Roeseler E; Heigl F; Grützmacher P; Blume H; Vogt A;
Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):44-49. PubMed ID: 28233268
[TBL] [Abstract][Full Text] [Related]
15. Rationale and design of MultiSELECt: A European Multicenter Study on the Effect of Lipoprotein(a) Elimination by lipoprotein apheresis on Cardiovascular outcomes.
Hohenstein B; Julius U; Lansberg P; Jaeger B; Mellwig KP; Weiss N; Graehlert X; Roeder I; Ramlow W
Atheroscler Suppl; 2017 Nov; 30():180-186. PubMed ID: 29096835
[TBL] [Abstract][Full Text] [Related]
16. Lipoprotein(a)--An independent causal risk factor for cardiovascular disease and current therapeutic options.
Kassner U; Schlabs T; Rosada A; Steinhagen-Thiessen E
Atheroscler Suppl; 2015 May; 18():263-7. PubMed ID: 25936335
[TBL] [Abstract][Full Text] [Related]
17. Kinetics of Lipoprotein(a) in patients undergoing weekly lipoprotein apheresis for Lp(a) hyperlipoproteinemia.
Tselmin S; Müller G; Schatz U; Julius U; Bornstein SR; Hohenstein B
Atheroscler Suppl; 2017 Nov; 30():209-216. PubMed ID: 29096840
[TBL] [Abstract][Full Text] [Related]
18. The incidence of cardiovascular events is largely reduced in patients with maximally tolerated drug therapy and lipoprotein apheresis. A single-center experience.
Sampietro T; Sbrana F; Bigazzi F; Ripoli A; Dal Pino B; Pasanisi EM; Petersen C; Coceani M; Luciani R; Pianelli M
Atheroscler Suppl; 2015 May; 18():268-72. PubMed ID: 25936336
[TBL] [Abstract][Full Text] [Related]
19. Adverse events of lipoprotein apheresis and immunoadsorption at the Apheresis Center at the University Hospital Dresden.
Dittrich-Riediger J; Schatz U; Hohenstein B; Julius U
Atheroscler Suppl; 2015 May; 18():45-52. PubMed ID: 25936304
[TBL] [Abstract][Full Text] [Related]
20. Lipoprotein apheresis in patients with peripheral artery disease and lipoprotein(a)-hyperlipoproteinemia: 2-year follow-up of a prospective single center study.
Poller WC; Berger A; Dreger H; Morgera S; Enke-Melzer K
Atheroscler Suppl; 2017 Nov; 30():174-179. PubMed ID: 29096834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
